Open access · CC-BY
via OpenAlex
Metabolic Reprogramming in Triple-Negative Breast Cancer
Xiangyu Sun, Mozhi Wang, Mengshen Wang, Xueting Yu, Jingyi Guo, Tie Cheng Sun, Xinyan Li, Litong Yao, Haoran Dong, Yingying Xu
Frontiers in Oncology · 2020 · ▲ 250 citations
Abstract
Metabolic reprogramming is an emerging hallmark of cancer cells, in which cancer cells exhibit distinct metabolic phenotypes to fuel their proliferation and progression. The significant advancements made in the area of metabolic reprogramming make possible new strategies for overcoming malignant cancer, including triple-negative breast cancer. Triple-negative breast cancer (TNBC) is associated with high histologic grade, aggressive phenotype, and poor prognosis. Even though triple-negative breast cancer patients benefit from standard chemotherapy, they still face high recurrence rates and are more likely to develop resistance to chemotherapeutic drugs. Therefore, there is an urgent need to explore vulnerabilities of triple-negative breast cancer and develop novel therapeutic drugs to improve clinical outcomes for triple-negative breast cancer patients. Metabolic reprogramming may provide promising therapeutic targets for the treatment of triple-negative breast cancer. In this paper, we primarily discuss how triple-negative breast cancer cells reprogram their metabolic phenotype and that of stromal cells in the microenvironment to survive under nutrient-poor conditions. Considering that metastasis and chemoresistance are the main contributors to mortality in triple-negative breast cancer patients, we also focus on the role of metabolic adaption in mediating metastasis and chemoresistance of triple-negative breast cancer tumors.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3389/fonc.2020.00428
- Canonical
- link ↗
- Fetched
- 2026-09-30 MST
Cite this
APA
Sun, X., Wang, M., Wang, M., Yu, X., Guo, J., Sun, T.C., Li, X., Yao, L., Dong, H., & Xu, Y. (2020). Metabolic Reprogramming in Triple-Negative Breast Cancer. <em>Frontiers in Oncology</em>. https://doi.org/10.3389/fonc.2020.00428
Vancouver
Sun X, Wang M, Wang M, Yu X, Guo J, Sun TC, et al. Metabolic Reprogramming in Triple-Negative Breast Cancer. Frontiers in Oncology. 2020. doi:10.3389/fonc.2020.00428.
BibTeX
@article{xiangyu2020Metabo,
title = {Metabolic Reprogramming in Triple-Negative Breast Cancer},
author = {Xiangyu Sun and Mozhi Wang and Mengshen Wang and Xueting Yu and Jingyi Guo and Tie Cheng Sun and Xinyan Li and Litong Yao and Haoran Dong and Yingying Xu},
journal = {Frontiers in Oncology},
year = {2020},
doi = {10.3389/fonc.2020.00428},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Molecular Cancer Research 2011
Open access · OA
Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers
MedComm 2023
Open access · CC-BY
Metabolic reprogramming in cancer: Mechanisms and therapeutics
Ju Qiu 2023
Open access · US-GOV
Comparison of Frailty Screening Performance and Predictive Validity of Adverse Health Outcomes in Breast Cancer Patients Using Frailty Screening Tools
Frontiers in Cell and Developmental Biology 2025
Open access · CC-BY
Intercellular communication between extracellular vesicles from conditioned macrophages and breast cancer cells drives endocrine therapy resistance
Breast Cancer Research 2020
Open access · CC-BY
Triple-negative breast cancer molecular subtyping and treatment progress
Metabolites 2023
Open access · CC-BY